PFGTF.US Pacific Edge Limited

Healthcare Biotechnology USA Stocks
0.1349 USD
Close of Nov 15, 2026
0.0678 0.2327
Market cap
USD 168M
P/E
-
P/B
28.27x
ROE
-335.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Mar 2026.

Is PFGTF.US undervalued?

Graham number

The Graham number of Pacific Edge Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pacific Edge Limited fundamental analysis

No fundamental analysis for Pacific Edge Limited yet.

Pacific Edge Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pacific Edge Limited

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbl…

Full company profile